However, the clinical benefit of tapering versus abrupt discontinuation has not been formally studied for tirzepatide
Similarly, analyses of secondary cognitive and functional outcomes did not reveal meaningful differences between treatment and placebo groups, indicating no clinically significant benefit in cognition or daily functioning over the primary treatment period
#Pharmacy #PharmD #GLP1 #ObesityMedicine #MedicationSafety #PatientCare #WeightManagement To view or add a comment, sign in Prescribing a GLP-1 drug is the easy part
MARCH1 regulates insulin sensitivity by controlling cell surface insulin receptor levels
CSF levels of transthyretin (TTR, a clearance protein produced in the choroid plexus) have been found to be increased in Lewy body diseases, including PD, PDD, and DLBD in relation with controls (Maetzler et al., 2012)